Associated Papers
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Bardia A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.
Kim JW et al.
Cancer Research and Treatment, 2023
Select a paper to view details